Dabrafenib
Tafinlar-Mekinist Approved for BRAF-Positive Anaplastic Thyroid Cancer
The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the ...
MAY 8, 2018
Tafinlar + Mekinist, Companion Dx Approved for BRAF V600E–Mutant Metastatic NSCLC
Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) with Oncomine Dx Target Test ...
JUNE 23, 2017
Load more